AIM AND SCOPE
The Journal of Cancer Research and Therapeutic Oncology aims to serve as a comprehensive international platform for the publication of high-quality research, clinical studies, and scholarly contributions in the fields of cancer research, oncology, and therapeutic sciences. The journal is dedicated to advancing scientific understanding of cancer biology, tumor development, carcinogenesis, and cancer progression, while promoting the development of innovative diagnostic, preventive, and therapeutic strategies for various malignancies and oncologic disorders. It seeks to bridge the gap between basic cancer research and clinical oncology by encouraging translational, multidisciplinary, and evidence-based studies that contribute to improved patient outcomes, early detection, personalized treatment, and precision oncology.
The journal also aims to foster collaboration among oncologists, cancer researchers, clinicians, surgeons, radiologists, pathologists, pharmacologists, and healthcare professionals worldwide, facilitating the exchange of emerging knowledge and advancements in oncology and cancer therapeutics. Emphasis is placed on scientific excellence, ethical research practices, and the dissemination of findings with significant clinical, translational, and public health impact in the field of cancer care and management.
Scope of the journal
The journal covers a broad range of topics related to cancer research and therapeutic oncology. The primary areas of interest include, but are not limited to, the following:
Cancer biology, molecular oncology, cellular oncology, tumor biology, cancer genetics, cancer genomics, oncogenomics, epigenetics in cancer, cancer proteomics, transcriptomics, metabolomics, functional genomics, comparative oncology, cancer immunology, immuno-oncology, tumor microenvironment, angiogenesis, metastasis, carcinogenesis, cancer stem cells, signal transduction pathways, apoptosis, cell cycle regulation, DNA damage and repair, chromosomal abnormalities, oncogenes, tumor suppressor genes, biomarkers in cancer, molecular diagnostics, liquid biopsy, precision oncology, personalized cancer therapy, translational oncology, clinical oncology, medical oncology, surgical oncology, radiation oncology, pediatric oncology, gynecologic oncology, hematologic oncology, neuro-oncology, thoracic oncology, gastrointestinal oncology, breast oncology, urologic oncology, dermatologic oncology, endocrine oncology, and rare cancers.
The journal also welcomes research in cancer prevention and epidemiology including cancer risk factors, environmental carcinogenesis, occupational cancers, lifestyle-associated cancers, viral oncology, cancer screening, early detection, public health oncology, cancer registries, population-based studies, and global cancer burden.
Therapeutic research areas include chemotherapy, targeted therapy, immunotherapy, hormone therapy, radiotherapy, radionuclide therapy, gene therapy, cell therapy, CAR-T cell therapy, stem cell transplantation, nanomedicine, drug delivery systems, vaccine development, biologics, monoclonal antibodies, combination therapies, supportive oncology, palliative care, rehabilitation in cancer care, survivorship studies, and emerging therapeutic technologies.
The journal encourages studies involving advanced diagnostic and analytical technologies such as next-generation sequencing, whole genome sequencing, bioinformatics, computational oncology, artificial intelligence in cancer research, machine learning applications in oncology, digital pathology, radiomics, imaging technologies, systems biology, and multi-omics integration.
Additional areas of interest include clinical trials, translational medicine, pharmacology, pharmacogenomics, resistance mechanisms, therapeutic biomarkers, drug discovery and development, toxicology, precision diagnostics, cancer pathology, laboratory oncology, biostatistics, and evidence-based oncology.
The journal recognizes the importance of ethical, legal, and social aspects of cancer research and clinical practice. Topics such as patient consent, data privacy, equitable access to cancer care, cancer health disparities, policy and regulation in oncology, psychosocial oncology, cancer education, and quality of life research are also welcomed.
Types of Manuscripts
The journal accepts a variety of manuscript types including original research articles, review articles, systematic reviews, meta-analyses, case reports, case series, short communications, technical notes, clinical studies, editorials, perspectives, and letters to the editor.
Global Perspective and Inclusivity
The journal adopts a global perspective by encouraging submissions from researchers, clinicians, and healthcare professionals across diverse geographic regions. Cancer remains a major global health challenge, with variations in incidence, genetics, environmental exposure, healthcare access, and treatment outcomes among populations worldwide.
By promoting international collaboration and multidisciplinary research, the journal seeks to address disparities in cancer prevention, diagnosis, and treatment. Studies highlighting regional cancer patterns, population-specific findings, public health interventions, and innovative healthcare strategies are highly encouraged.
Ethical Standards and Scientific Integrity
The journal is committed to maintaining the highest standards of scientific integrity, ethical research conduct, and methodological rigor. Authors are expected to adhere to established ethical guidelines for clinical and experimental studies, including patient safety, informed consent, and transparency in reporting.
The peer review process ensures unbiased evaluation and supports the publication of reliable, accurate, and impactful scientific work that contributes to advancements in cancer research and therapeutic oncology.
Education and Knowledge Dissemination
The journal aims to serve as a valuable educational resource for oncologists, researchers, healthcare professionals, educators, and students. Educational reviews, clinical updates, and interdisciplinary perspectives that simplify complex oncological concepts and promote continuous learning are encouraged.
Encouragement of Multidisciplinary Collaboration
Cancer research requires collaboration across multiple scientific and clinical disciplines. The journal promotes multidisciplinary and collaborative studies involving oncologists, geneticists, molecular biologists, pharmacologists, bioinformaticians, epidemiologists, pathologists, and healthcare professionals.
Such collaborative efforts contribute to comprehensive insights, innovative therapeutic approaches, and improved clinical outcomes for cancer patients.
Adaptability to Emerging Scientific Advances
The field of oncology is rapidly evolving with continuous advancements in molecular medicine, immunotherapy, precision oncology, and digital healthcare technologies. The journal remains adaptable to these scientific developments by expanding its scope to include emerging research areas and novel therapeutic strategies.
The Journal of Cancer Research and Therapeutic Oncology is committed to promoting excellence in cancer research and clinical care by maintaining a broad, inclusive, and interdisciplinary scope. Through the publication of innovative and impactful research, the journal aims to contribute to scientific progress and improve outcomes for cancer patients worldwide.
